The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
Abstract
Nonmyeloablative regimens for allogeneic hematopoietic cell transplantation (HCT) have been developed for patients ineligible for myeloablative conditioning. We compared regimen-related toxicities (RRTs) and nonrelapse mortality (NRM) in 73 nonmyeloablative and 73 myeloablative recipients of HLA-matched related donor HCT, using the National Cancer Institute (NCI) Common Toxicity Criteria. Nonmyeloablative regimens were 2 Gy total body irradiation (TBI), either alone (n = 40) or combined with fludarabine, 30 mg/m2/d for 3 days (n = 33). Posttransplantation immunosuppression included mycophenolate mofetil and cyclosporine. Myeloablative regimens consisted mostly of cyclophosphamide + TBI or busulfan + cyclophosphamide, followed by posttransplantation methotrexate and cyclosporine. Nonmyeloablative patients were at higher risk than ablative patients because of greater age, longer time from diagnosis to HCT, more frequent preceding high-dose HCT, and higher pretransplantation Charlson comorbidity scores. Nevertheless, they experienced significantly less severe toxicities in 7 organs/systems: hematologic, gastrointestinal, hepatic, hemorrhage, infection, metabolic, and pulmonary. This translated into less NRM at day 100 (3% versus 23%, P = 10-4) and 1 year (16% versus 30%, P = .04). In multivariate analysis, the strongest factor predicting lessened RRT and NRM was nonmyeloablative conditioning, whereas high pretransplantation comorbidity scores predicted higher NRM. In conclusion, nonmyeloablative regimens had lower RRT and NRM and could be considered for comparative studies, including younger patients with more favorable Charlson comorbidity scores.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
Statistical Models Based on Counting Processes
Bry, X., Andersen, P. K., Borgan, Ø., Gill, R. D., Keiding, N., & Borgan, O. (1997) · Population (French Edition) · doi:10.2307/1534625 · Cited by 2,884
Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., et al. (1998) · Blood · doi:10.1182/blood.v91.3.756 · Cited by 2,071
Storb, R., Deeg, H. J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C. D., Clift, R., Doney, K., Farewell, V., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603203141201 · Cited by 1,411
Self-citationMcSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3390 · Cited by 1,389
Self-citationMcDonald, G. B., Hinds, M. S., Fisher, L. D., Schoch, H. G., Wolford, J. L., Banaji, M., Hardin, B. J., Shulman, H. M., & Clift, R. A. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-4-199302150-00003 · Cited by 1,202
Childs, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., Read, E. J., Tisdale, J., Dunbar, C., Linehan, W. M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009143431101 · Cited by 998
Bensinger, W. I., Martin, P. J., Storer, B., Clift, R., Forman, S. J., Negrin, R., Kashyap, A., Flowers, M. E. D., Lilleby, K., Chauncey, T. R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101183440303 · Cited by 962
Self-citation
Cited by
Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood · doi:10.1182/blood-2005-05-2004 · Cited by 2,969
Self-citationFerrara, J. L., Levine, J. E., Reddy, P., & Holler, E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60237-3 · Cited by 2,464
Drug therapy for acute myeloid leukemia
Tallman, M. S., Gilliland, D. G., & Rowe, J. M. (2005) · Blood · doi:10.1182/blood-2005-01-0178 · Cited by 661
Cornelissen, J. J., Gratwohl, A., Schlenk, R. F., Sierra, J., Bornhäuser, M., Juliusson, G., Råcil, Z., Rowe, J. M., Russell, N., Mohty, M., et al. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.150 · Cited by 400
Metadata
- Authors
- Diaconescu, R., Flowers, C. R., Storer, B., Sorror, M. L., Maris, M. B., Maloney, D. G., Sandmaier, B. M., & Storb, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-09-01
- Volume
- 104
- Issue
- 5
- Pages
- 1550-1558
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2087380692
- Cited by
- 322
- References
- 43
- FWCI
- 23.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. https://app.cochat.ai/papers/10.1182/blood-2004-03-0804
- The paper
- Diaconescu, R., Flowers, C. R., Storer, B., Sorror, M. L., Maris, M. B., Maloney, D. G., Sandmaier, B. M., & Storb, R. (2004). Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. https://doi.org/10.1182/blood-2004-03-0804
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.